A Phase 1/2 interventional study of Pegtibatinase and Placebo in Homocystinuria, sponsored by Travere Therapeutics, Inc.. Recruiting at 12 sites in 3 countries. Open to participants aged 5 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-10.
Sponsored by Travere Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment
Researchers are looking for a better way to treat people who have classical homocystinuria (HCU), a rare condition that is passed down by parents (or "genetic condition"). It is caused by changes in the cystathionine beta-synthase (or "CBS") gene and prevents an enzyme from working correctly in the body. This enzyme breaks down a substance called homocysteine (from dietary methionine found in protein) and keeps both homocysteine and methionine at normal levels. When this enzyme is not working, homocysteine and methionine build up in the blood, which spreads into different tissues of the body and stops these body tissues from working normally.
People with HCU can experience problems with vision, bones, blood vessels, and cognitive function (the ability to think, learn, and remember). Treatments available for HCU, such as a low protein diet and betaine (Cystadane®), help reduce homocysteine levels. The diet is a low methionine diet and a methionine-free protein supplement (a product that provides extra protein to help meet daily protein needs). These treatments are either not sufficient or are hard to take for many patients.
Pegtibatinase was developed by scientists to be a version of the CBS enzyme that can be given to people with HCU. Researchers believe that giving pegtibatinase to people with HCU already getting medical treatment (or "standard of care") may reduce their homocysteine levels.
This study is split into 7 different groups getting different amounts of drug. The first 6 groups have already finished the study.
Group 7 plans to enroll participants from the US (virtual and in-person), France, and Qatar.
Primary Objective - Cohorts 1-6
Researchers are performing this study to learn if pegtibatinase is safe and tolerable (how it makes participants feel).
Researchers will use medical examination, blood tests, and urine tests to measure side effects (unwanted health problems that may or may not be related to the study treatment), changes in laboratory tests and in the electrical activity of the heart (as measured by electrocardiogram or "ECG"), and if the body makes antibodies to fight against pegtibatinase. Antibodies are proteins that the body makes that may stop pegtibatinase from working or may cause side effects.
Secondary Objectives - Cohorts 1-6
Researchers also want to learn about:
Cohort 7 Objectives
Group 7 is open to children aged 5 to 11 years old (or "pediatric participants") who meet the requirements for the study.
Researchers are performing this part of the study with Group 7 to learn if pegtibatinase is safe and tolerable (how it makes participants feel) and if it increases antibody levels when it is given to children with HCU.
Researchers will use blood tests and physical examinations to measure side effects that happen during the study, changes in laboratory tests, electrical activity of the heart, antibody levels, vital signs, and the number of pediatric participants that have too high or too low levels of methionine. Researchers will use questionnaires to measure the number of pediatric participants that need more protein in their diet.
Researchers are performing this part of the study with Group 7 because they also want to learn about:
Study Population and Treatments
This study will include children and adults from 5 to 65 years old with HCU. Participants in Groups 1 to 6 were aged 12 to 65 years old, and Group 7 participants will be aged 5 to 11 years old. Participants in the study will take their standard of care treatment.
Groups 1 to 6 have completed this study already. For these groups, 24 participants aged 12 to 65 years old who met the requirements of the study were split into 1 of the 6 groups. For each group, 3 participants were chosen to take pegtibatinase for every 1 participant chosen to take an injection that does not have any medicine in it (or "placebo"). Participants were assigned to pegtibatinase or placebo by chance, like the flip of a coin. This is called "randomization". Neither the researchers nor the participants knew which treatment they were getting until the study was completed. This is known as a "double-blind" approach.
Group 7 is open and will be conducted globally. It will include 10 to 15 pediatric participants aged 5 to 11 years old who meet the requirements of the study. All participants in this group will receive pegtibatinase. All participants will know that this is the treatment that they receive. This is called an "open label" approach. The treatment period will be separated into 3 parts: Part A, Part B, and Part C. Each part will test a different dose of pegtibatinase. After each part, pediatric participants who meet specific requirements will move to the next part. If the pediatric participants do not meet specific requirements to move to the next part, they will have the option to join the ENSEMBLE study (NCT06431893) and continue taking that same dose.
Pegtibatinase or placebo will be given as an injection under the skin (or "subcutaneous injection"). Doses for each group are shown below.
Study Duration and Visits
Participants in Groups 1 to 6 were in the study for up to 158 weeks, including the screening period of up to 8 weeks, a double-blind treatment period of up to 12 weeks, and an extension period of up to 138 weeks. A continuation study called ENSEMBLE was available to participants. Participants were offered to join the ENSEMBLE study before they finished the extension period of the COMPOSE study.
Pediatric participants in Group 7 may be in the study for up to 42 weeks, including the screening period of up to 10 weeks, open-label treatment period of up to 20 weeks, and up to 12 weeks of additional treatment at the same dose if the ENSEMBLE study is not yet open.
If participants in Group 7 meet all the requirements of the study, they will have up to 53 visits to a study center or at home. If the ENSEMBLE study is not yet open at their site, they can have up to 23 more visits to continue treatment.
These visits can include:
Safety / Adverse Events
Researchers will keep track of any medical problems that a participant has during a study (or "adverse event"). All participants in this study will have regular laboratory tests, health checkups, and site visits to watch for health risks and measure safety.
Benefit-Risk Conclusion Researchers have worked to reduce risks to participants in this study. They believe the risks of taking pegtibatinase in this study are justified by the potential benefits that they think pegtibatinase may have for people with HCU.
20 studies on the registry are indexed under Homocystinuria; 5 are open to participants now.
This study's planned enrollment of 39 is above the median of 22 across 12 interventional studies indexed under Homocystinuria.
Browse Homocystinuria studies →Travere Therapeutics, Inc. is the lead sponsor of 14 studies on the registry; 4 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age
Diagnosis of classical homocystinuria (HCU)
Plasma total homocysteine (tHcy)
Exclusion Criteria:
Cohort 7 only:
All Cohorts:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
Drug: Pegtibatinase
Double-Blind Treatment Cohorts (≥12 to ≤65 years)
Drug: Placebo
Pediatric Open-label Treatment Cohort (≥5 to \<12 years)
Drug: Pegtibatinase
Pegtibatinase sterile solution for subcutaneous injection
Also known as: TVT-058, OT-58, PEG modified CBS, PEG htCBS C15S, htCBS C15S ME-200GS
Normal saline for subcutaneous injection
Incidence of AEs
Incidence of AEs (by type, severity and relationship to study drug)
Time frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Anti-pegtibatinase antibodies
Presence and levels of anti-pegtibatinase antibodies in plasma as measured by antibody titers
Time frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Anti-PEG antibodies
Presence and levels of anti-PEG antibodies in plasma as measured by antibody titers
Time frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Incidence of hypermethioninemia (Cohort 7 only)
The number and percentage of participants who develop hypermethioninemia during treatment, based on plasma methionine concentrations exceeding the protocol-defined threshold. Participants meeting the protocol-defined threshold may undergo dietary management or study treatment modifications, as appropriate.
Time frame: First dose through End of Treatment (up to Week 32)
Incidence of hypomethioninemia (Cohort 7 only)
The number and percentage of participants who develop hypomethioninemia during treatment, based on plasma methionine concentrations below the protocol-defined threshold. Participants meeting the protocol-defined threshold may receive dietary protein supplementation or study treatment modifications, as appropriate.
Time frame: First dose through End of Treatment (up to Week 32)
The proportion of participants requiring dietary protein rescue (Cohort 7 only)
The proportion of participants who require initiation of dietary protein supplementation during study treatment to manage protocol-defined low plasma methionine concentrations.
Time frame: First dose through End of Treatment (up to Week 32)
Changes in pegtibatinase levels
Changes in pegtibatinase levels following single and repeat administration at specified timepoints
Time frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in Met cycle metabolites levels - tHcy
Changes in total homocysteine levels in micromoles
Time frame: • Cohorts 1-6: Through double-blind study completion, approximately 10 months per patient • Cohort 7: First dose through End of Treatment (up to 32 weeks)
Changes in Met cycle metabolites levels - total Cys (Cohorts 1-6 Only)
Changes in total cysteine levels in micromoles
Time frame: Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Me (Cohorts 1-6 Only)
Changes in methionine levels in micromoles
Time frame: Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Cth (Cohorts 1-6 Only)
Changes in cystathionine levels in micromoles
Time frame: Through double-blind study completion, approximately 10 months per patient
Changes in Met cycle metabolites levels - Phe (Cohorts 1-6 Only)
Changes in phenylalanine levels in micromoles
Time frame: Through double-blind study completion, approximately 10 months per patient
Descriptive ophthalmology examination findings (Cohorts 1-6 Only)
Comprehensive ophthalmological examination (for each eye: visual acuity \[myopia, hyperopia, exotropia\], slit lamp examination \[ectopic lentis, cataracts, corneal abrasion, and uveitis\], retinal examination \[retinal degeneration, retinal detachment, retinitis pigmentosa, uveitis)\]). Assessment of presence and severity of findings.
Time frame: Through double-blind study completion, approximately 10 months per patient
Bone densitometry using dual-energy X-ray absorptionmetry (DEXA) scans (Cohorts 1-6 Only)
Time frame: Through double-blind study completion, approximately 10 months per patient
Cognitive assessments using the National Institutes of Health Toolbox Cognition Battery score (Cohorts 1-6 Only)
Time frame: Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life in Neurological Disorders [Neuro-QoL] (Cohorts 1-6 Only)
The Quality of Life in Neurological Disorders \[Neuro-QoL\] includes Anxiety Short Form, Depression Short Form, Satisfaction with Social Roles Short Form, Cognition Function Short Form for 18+ years of age; Anxiety Short Form, Depression Short Form, Social Relations - Interaction with Peers Short Form, and Cognitive Function Short Form for Ages 12 to 17 years old
Time frame: Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life by 36-Item Short Form Survey [SF-36] (Cohorts 1-6 Only)
Time frame: Through double-blind study completion, approximately 10 months per patient
Patient Reported Outcome (PRO): Quality of Life by EuroQol 5-Dimentional Instrument [EQ 5D] (Cohorts 1-6 Only)
Time frame: Through double-blind study completion, approximately 10 months per patient
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Not enrolling at this site.
Plan to share: Yes — Requests for clinical trial data, including language stating its intended use, should be directed to datarequest@travere.com. If approved, the requested information will be provided to the requestor after signing a data access agreement. Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication. Travere reserves the right to decline or recommend modifications to a request if it does not comply with the data sharing policy or if it is determined that the request is made by a biased source.
Time frame: Requests can be made following completion of the study and full publication of the study data in a peer reviewed journal for up to 36 months following its publication.
Access criteria: Requires submission and approval of intended use and a data sharing agreement.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pegtibatinase
Travere Therapeutics, Inc.